Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | C1R | P00736 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078098 | 1.00 | ELANE (0.54) | ELANEMAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL2077529 | 1.00 | ELANE (0.54) | ELANEMAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL2076590 | 1.00 | ELANE (0.54) | ELANEMAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL2076594 | 1.00 | ELANE (0.54) | ELANEMAPTKDM4EALDH1A1MEN1 | |
| Cetilistat SCHEMBL367612 | 1.00 | ELANE (0.54) | ELANEMAPTKDM4EALDH1A1MEN1 | |
| Cetilistat SCHEMBL29352962 | 1.00 | ELANE (0.54) | ELANEMAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL2076646 | 1.00 | ELANE (0.54) | ELANEMAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL2078034 | 1.00 | ELANE (0.54) | ELANEMAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL2078347 | 1.00 | ELANE (0.54) | ELANEMAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL12778013 | 0.95 | ELANE (0.59) | ELANEMAPTKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143977-B3 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE BV (NL) | 2012-10-24 | — | — | EP | claimed |
| US-7825113-B2 | An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis | NORGINE B.V. (NL) | 2010-11-02 | — | — | US | claimed |
| EP-1143977-B1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LTD (GB) | 2005-04-20 | — | — | EP | claimed |
| US-20030195206-A1 | An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis | NORGINE B.V. (NL) | 2003-10-16 | — | — | US | claimed |
| US-6624161-B2 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | ALIZYME THERAPEUTICS LIMITED (GB) | 2003-09-23 | — | — | US | claimed |
| US-20030138396-A1 | Method of treating high plasma cholesterol levels | HADVARY PAUL (CH) | 2003-07-24 | — | — | US | claimed |
| US-20030027821-A1 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | NORGINE B.V. (NL) | 2003-02-06 | — | — | US | claimed |
| CN-1359378-A | 2-oxo-4H-3, 1-benzoxazine 4-ones for the treatment of obesity | ALIZYME THERAPEUTICS LTD (GB) | 2002-07-17 | — | — | CN | claimed |
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| US-20130079391-A1 | LIPASE INHIBITING COMPOSITION | Hoffman-La Rochc Inc. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8372430-B2 | comprises stiffening agents for ameliorating side effects associated with adminstration of lipase inhibitors (anal leakage of undigested fat or oil); for treatment of diabetes | THE PROCTER & GAMBLE COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8343543-B2 | Lipase inhibiting composition | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20020035089-A1 | Orlistat compositions | CHEPLAPHARM ARZNEIMITTEL GMBH (DE) | 2002-03-21 | — | — | US | disclosed |
| WO-2002011719-A2 | LIPASE INHIBITORS FOR THE TREATMENT OF DYSPEPSIA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-14 | — | — | WO | disclosed |
| US-20020018812-A1 | Process for preparing a pharmaceutical composition | CHEPLAPHARM ARZNEIMITTEL GMBH (DE) | 2002-02-14 | — | — | US | disclosed |
| WO-2002009815-A2 | NEW PHARMACEUTICAL COMPOSITION | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002009814-A2 | NEW USE OF LIPASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002000201-A2 | METHOD FOR PREPARING A COMPOSITION | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035089-A1 | Orlistat compositions | LIPC, CEL, PNLIP | ELANE 734/4885MAPT 287/4885KDM4E 3916/4885 |
| US-20130079391-A1 | LIPASE INHIBITING COMPOSITION | LIPC, PNLIP, CEL | ELANE 180/4885MAPT 2670/4885KDM4E 2444/4885 |
| US-20030027821-A1 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | CYP2F1, BBOX1, CES1 | ELANE 1134/4885MAPT 4061/4885KDM4E 1177/4885 |
| US-20030195206-A1 | An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis | CES1, LIPC, PNLIP | ELANE 1412/4885MAPT 2799/4885KDM4E 1682/4885 |
| US-20030138396-A1 | Method of treating high plasma cholesterol levels | LIPA, PNLIP, LIPC | ELANE 596/4885MAPT 808/4885KDM4E 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.